Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Revenue of Precision BioSciences, Inc. (DTIL)
Revenue in 2023 (TTM): $48.73 M
According to Precision BioSciences, Inc.'s latest financial reports the company's current revenue (TTM) is $48.73 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Precision BioSciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $48.73 M | $40.47 M | $-35,481,000 | $-42,527,000 | $-69,765,000 |
| 2022 | $25.1 M | $16.09 M | $-98,472,000 | $-111,637,000 | $-122,908,000 |
| 2021 | $115.53 M | $115.53 M | $-28,813,000 | $-30,602,000 | $-30,918,000 |
| 2020 | $24.29 M | $24.29 M | $-99,193,000 | $-109,006,000 | $-109,006,000 |
| 2019 | $22.24 M | $22.24 M | $-87,378,000 | $-92,877,000 | $-83,301,000 |
| 2018 | $10.88 M | $10.88 M | $-45,558,000 | $-46,037,000 | $-46,037,000 |
| 2017 | $6.48 M | $6.48 M | $-20,303,000 | $-21,102,000 | $-21,102,000 |
| 2016 | $7.02 M | $7.02 M | $-8,188,000 | $-8,256,000 | $-8,250,999 |